Veronique D/iStock Editorial via Getty Images The European Patent Office has upheld the validity of a key patent for Biogen's ( NASDAQ: BIIB ) multiple sclerosis drug Tecfidera (dimethyl fumarate). As a result, the treatment will have marketing protection in the European Union through Feb. 3, 2025.
The EPO.
